1. Analyst View
2. Global Generic Drugs Market
2.1 Market Size & Growth
2.2 By Region
3. United States Generic Drugs Market
3.1 Most Potential Generic Drugs Market
3.2 Market Size & Growth
3.2.1 Pharmaceutical Market
3.2.1.1 By Therapeutic Category
3.2.1.2 By Drugs Category
3.2.1.2.1 Branded Drugs
3.2.1.2.2 Branded Generics
3.2.1.2.3 Unbranded Generics
3.2.1.3 Unbranded Generics witnessing Fastest Growth
4. Regulatory Environment
4.1 Drug Efficacy Study Implementation (DESI) Program
4.2 Hatch-Waxman Act
4.3 Patent Infringement Litigations
4.4 Para IV & the 180-day Marketing Exclusivity
4.5 FDA Requirements
4.6 Generic Initiative for Value & Efficiency (GIVE)
5. Industry Analysis
5.1 Driving Forces
5.1.1 Huge Cost Savings
5.1.2 Patent Expiries
5.1.3 Favorable Political Environment
5.1.4 Ageing Population
5.1.5 Large Uninsured Population
5.1.6 Obesity
5.2 Opportunities
5.2.1 Patent Expiry of Key Drugs
5.2.2 Biogenerics
5.2.3 Contract Manufacturing
5.2.4 Drugs Packaging
5.2.5 Drugs Delivery
5.3 Challenges
5.3.1 Lawsuits
5.3.2 High Entry Barriers
5.3.3 Price Erosion & Depleting Margins
5.3.4 Authorized Generics
6. Future Outlook (2007-2011)
6.1 Driving & Restraining Forces
6.2 Sales
7. Competitive Landscape
7.1 Market Share of Key Players
7.2 Profile of Key Players
7.2.1 Teva Pharmaceutical Industries Limited
7.2.2 Watson Pharmaceuticals, Inc.
7.2.3 Mylan Laboratories Inc.
7.2.4 Sandoz Inc.
7.2.5 Actavis Group hf
8. Supporting Databases
8.1 Macroeconomic Indicators
8.2 Population
8.3 Demographics
8.4 Healthcare Expenditure
8.5 Healthcare Infrastructure
8.6 Major Causes of Mortality
